JC virus in CD34+ and CD19+ cells in patients with multiple sclerosis treated with natalizumab.
about
Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert groupImmune System Involvement in the Pathogenesis of JC Virus Induced PML: What is Learned from Studies of Patients with Underlying Diseases and Therapies as Risk FactorsProgressive multi-focal leucoencephalopathy - driven from rarity to clinical mainstream by iatrogenic immunodeficiency.Progressive Multifocal Leukoencephalopathy in HIV-Uninfected Individuals.Extended interval dosing of natalizumab in multiple sclerosis.A link between long-term natalizumab dosing in MS and PML: Putting the puzzle togetherViral miRNAs in plasma and urine divulge JC polyomavirus infection.Antibodies reacting with JCPyV_VP2 _167-15mer as a novel serological marker for JC polyomavirus infection.Persistence and pathogenesis of the neurotropic polyomavirus JCCD49d antisense drug ATL1102 reduces disease activity in patients with relapsing-remitting MSImmunological Markers for PML Prediction in MS Patients Treated with NatalizumabJC virus quasispecies analysis reveals a complex viral population underlying progressive multifocal leukoencephalopathy and supports viral dissemination via the hematogenous route.Hematopoietic mobilization: Potential biomarker of response to natalizumab in multiple sclerosis.CD4 cell response to interval therapy with natalizumab.Opportunistic DNA Recombination With Epstein-Barr Virus at Sites of Control Region Rearrangements Mediating JC Virus Neurovirulence.Orderly Steps in Progression of JC Virus to Virulence in the Brain.Natalizumab Affects T-Cell Phenotype in Multiple Sclerosis: Implications for JCV ReactivationProgressive Multifocal Leukoencephalopathy in Primary Immune Deficiencies: Stat1 Gain of Function and Review of the Literature.Broadly neutralizing human monoclonal JC polyomavirus VP1-specific antibodies as candidate therapeutics for progressive multifocal leukoencephalopathyNatalizumab-induced POU2AF1/Spi-B upregulation: A possible route for PML development.Increased Prevalence of Human Polyomavirus JC Viruria in Chronic Inflammatory Rheumatic Diseases Patients in Treatment with Anti-TNF α: A 18 Month Follow-Up Study.Sorting out the risks in progressive multifocal leukoencephalopathy.Immunology of progressive multifocal leukoencephalopathy.45 years after the discovery of human polyomaviruses BK and JC: Time to speed up the understanding of associated diseases and treatment approaches.High cumulative JC virus seroconversion rate during long-term use of natalizumab.CNS infections in 2014: Guns, germs, and will.Anti-JC virus antibody titres increase over time with natalizumab treatment.Primary Polyomavirus Infection, Not Reactivation, as the Cause of Trichodysplasia Spinulosa in Immunocompromised Patients.Monitoring the John Cunningham virus throughout natalizumab treatment in multiple sclerosis patients.Natalizumab exerts a suppressive effect on surrogates of B cell function in blood and CSF.Finger pointing to JC virus: a tale of two indexes.JC polyomavirus expression and bell-shaped regulation of its SF2/ASF suppressor during the follow-up of multiple sclerosis patients treated with natalizumab.Infections in Patients Receiving Multiple Sclerosis Disease-Modifying Therapies.
P2860
Q26780412-C5D4AFF3-FDDA-4495-8C90-8871B86F128DQ28085415-BC512CA5-E1ED-488A-9B04-F9E02D870CEDQ30235523-932D95E5-7E2A-4497-8419-380E0596633DQ30245002-20A40D9B-6C2F-4D37-B41D-1E0FFADC9DF4Q31049360-0C8C0203-B5AB-4331-8DAB-43906610C9A6Q33363188-16973034-EF58-4FAA-9299-64E270F38F28Q34208184-C9864AD4-21BD-4F77-B49B-165471EEF1B7Q34325718-0C62AEFE-5072-429C-AE8A-9B908EAC33CDQ34459843-E3D943C3-D899-40B3-B3EF-020CC7278533Q34556462-E77B0725-C83F-44CF-92D3-E494FF4F5C89Q34818048-73849D17-47C5-4D73-9DEE-F5A79626297FQ34991069-27C6A818-5F13-407A-B1FD-B4D2D075394EQ35400555-CAC35AED-4B96-4786-B5AC-D1CF443DE15EQ35619220-E9701F7D-B127-49D4-BD5B-1833A88F0ABBQ35874385-C5E0D1EA-ACA5-461A-946E-42E18E82C093Q36044561-761DEC52-BA5A-4DEB-82ED-CADE1B9DCE52Q36093592-F4EC95F2-08C4-49AB-B099-46871A1CFE24Q36715809-BD73F588-BF41-4CB0-A12E-1E6518C4D31BQ36764988-B4777626-757C-422F-851B-FE0BCFB8DDA2Q36767522-3D851A68-C2BF-47AB-B5E8-F6CA50BE2234Q36885632-67E0A8D5-5B78-4852-B08D-26345DA9BAD3Q38260098-2FF2C57F-DC38-4FA5-B22C-7464ABA4A5CFQ38367755-AC157AAB-396D-4B2B-86BF-488C24A1A5DCQ38801394-42D6772F-24C7-48E0-BE5C-A304B5D3E950Q39886328-2E4BFBDE-5795-4534-A46E-4F2AF355647EQ40253510-BD99D0F5-15FD-40D4-A6BE-BFE09C8924C3Q40451346-CA6DC861-6E49-4EA8-8D46-F597259337D7Q40557131-40BB0204-1EBC-4D2B-AA22-80BE7FA1EEB0Q40938497-98527ABA-32A8-4E08-A961-5503D115AB93Q42181572-1D1F93AE-E06A-43AA-9BD1-3094CA0E06C9Q42560354-0F57D07F-0A59-458D-B375-1EB0ABFE3757Q48246057-29A4B9E8-220E-4903-BA86-7F9C342BB429Q49906338-7457B377-4ADF-4521-A353-E046286456F6
P2860
JC virus in CD34+ and CD19+ cells in patients with multiple sclerosis treated with natalizumab.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
JC virus in CD34+ and CD19+ ce ...... osis treated with natalizumab.
@en
JC virus in CD34+ and CD19+ ce ...... osis treated with natalizumab.
@nl
type
label
JC virus in CD34+ and CD19+ ce ...... osis treated with natalizumab.
@en
JC virus in CD34+ and CD19+ ce ...... osis treated with natalizumab.
@nl
prefLabel
JC virus in CD34+ and CD19+ ce ...... osis treated with natalizumab.
@en
JC virus in CD34+ and CD19+ ce ...... osis treated with natalizumab.
@nl
P2093
P1433
P1476
JC virus in CD34+ and CD19+ ce ...... osis treated with natalizumab.
@en
P2093
Caroline Ryschkewitsch
Daniel Douek
Elliot M Frohman
Eugene O Major
Gina Remington
Julia Liebner
Kory Johnson
Maria Chiara Monaco
Molly Perkins
Nancy Monson
P304
P356
10.1001/JAMANEUROL.2014.63
P407
P577
2014-05-01T00:00:00Z